Treatment of non-hodgkin's lymphoma of low-grade malignancy with human fibroblast interferon

10 patients with advanced non-Hodgkin's lymphoma of low malignancy were treated with partially purified HulFN-beta. They received daily i.v. infusions of 4.5 X 10(6) IU for 4 weeks, followed by 9 X 10(6) IU daily for 2 weeks. Patients with stable disease during this period received consolidatio...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 2; no. 4; p. 193
Main Authors Siegert, W, Theml, H, Fink, U, Emmerich, B, Kaudewitz, P, Huhn, D, Böning, L, Abb, J, Joester, K E, Bartl, R, Riethmüller, G, Wilmanns, W
Format Journal Article
LanguageEnglish
Published Greece 01.07.1982
Subjects
Adult
Aged
Female
Humans
Interferon Type I - adverse effects
Interferon Type I - therapeutic use
Lymphoma - drug therapy
Male
Middle Aged
Online AccessGet more information

Cover

More Information
Summary:10 patients with advanced non-Hodgkin's lymphoma of low malignancy were treated with partially purified HulFN-beta. They received daily i.v. infusions of 4.5 X 10(6) IU for 4 weeks, followed by 9 X 10(6) IU daily for 2 weeks. Patients with stable disease during this period received consolidation therapy with 4.5 X 10(6) IU three times per week for a maximum of 20 weeks. Six out of 10 patients had progressive disease after the initial 6 week treatment and 4 had stable disease. Two of the latter developed progressive disease during consolidation therapy, one had a complete remission of minimal bone marrow involvement, and one was in partial remission with a loss of bone marrow infiltration but unchanged lymph node enlargement.
ISSN:0250-7005